Healthcare Professional Check

This website is intended for diabetes healthcare professionals. Click one of the options below to access the content.

You are here

Clinical Efficacy, Safety and Pharmacology of Ultra-Fast-Acting Insulins

In this course, you will learn about the rationale for developing ultra-fast-acting insulin analogues and their importance in achieving optimal glycaemic control. The clinical efficacy and safety data for fast-acting and ultra-fast-acting insulins will also be discussed. 

Now available

  • Baseline assessment

    Baseline assessment

    Please answer the baseline assessment questions in order to start this course.

    This course requires you to login. Don't have an account yet? Please register.
  • Webcast

    Efficacy and Safety of Ultra-Fast-Acting Insulin Analogues

    In this webcast, Professor Pieber explores key data from recent clinical trials on the efficacy and safety of ultra-fast-acting insulin analogues. He also discusses how these agents could provide an effective and flexible mealtime insulin option for use in the management of diabetes.

    Upon completion of this activity, participants should:

    • Understand the importance of improving glycaemic control in patients with types 1 and 2 diabetes
    • Understand the (available) efficacy and safety outcomes data for ultra-fast-acting insulin analogues
    • Be able to compare efficacy and safety data for fast-acting and ultra-fast-acting insulin analogues
    • Appreciate the convenience of ultra-fast-acting insulin analogues, and be aware of the challenges that remain concerning their use
    This course requires you to login. Don't have an account yet? Please register.
  • Roundtable

    Achieving Optimal Glycaemic Control: Can Insulin Deliver?

    In this activity, Professor Russell-Jones, Professor Danne, and Professor Liebl present two patient profiles to illustrate some of the practical challenges in achieving optimal glycaemic control in patients with diabetes. These profiles will highlight the importance of postprandial glucose levels, introduce strategies to help control postprandial glucose excursions, and educate on role of ultra-fast-acting insulin analogues.

    Learning objectives

    Following the roundtable discussion, healthcare professionals should:

    • Be aware of the importance of achieving postprandial glucose control when insulin therapy is being used
    • Discuss the role of ultra-fast-acting insulin analogues in the therapeutic armamentarium
    • Be able to compare pharmacokinetic and pharmacodynamic data for fast-acting and ultra-fast-acting insulin analogues
    • Recognize the convenience of ultra-fast-acting insulin analogues, and the challenges that remain regarding their use
    • Identify which patients will most benefit from treatment with ultra-fast-acting insulins
    This course requires you to login. Don't have an account yet? Please register.
  • Animated e-learning

    The evolution of insulin: from regular to fast to ultra-fast-acting

    In this animated eLearning module we outline the history of insulin development, discuss the time-action profiles of therapeutic insulin versus physiological insulin, and provide an overview of other ultra-fast-acting insulins in development.

    Learning objectives

    Upon completion of this activity, participants should be able to:

    • Identify the differences between regular, fast and ultra-fast-acting insulins  
    • Discuss the importance of more physiological meal-time insulin replacement  
    • Appreciate the improved pharmacokinetic/pharmacodynamic profile of the new ultra-fast-acting insulins  
    • Be aware of other ultra-fast-acting insulins in development
    This course requires you to login. Don't have an account yet? Please register.
  • Selected article

    Pharmacokinetic and pharmacodynamic properties of faster-acting insulin aspart versus insulin aspart across a clinically relevant dose range in subjects with type 1 diabetes mellitus

    In this activity, you will be introduced to three recently published articles selected for their further exploration of the pharmacological properties of ultra-fast-acting insulin analogues in patients with type 1 diabetes. These publications build upon what is currently known about the pharmacokinetic/pharmacodynamic profile of ultra-fast-acting insulin analogues by exploring their effects in special populations, such as elderly patients, and investigating how variations in dose may influence their ability to address postprandial hyperglycaemia.

    Learning objectives

    Following completion of this activity, participants should be able to:

    • Compare the pharmacokinetic/pharmacodynamic profile of fast-acting and ultra-fast-acting insulins when used in the insulin pump setting
    • Discuss the pharmacological properties of ultra-fast-acting insulins in elderly populations with type 1 diabetes
    • Describe the pharmacological properties of ultra-fast-acting insulins over a range of clinically relevant doses
    • Discuss the within-patient variability in the glucose-lowering effect of ultra-fast-acting insulins
    This course requires you to login. Don't have an account yet? Please register.
  • Selected article

    Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double-blind, crossover trial

    In this activity, you will be introduced to three recently published articles selected for their further exploration of the pharmacological properties of ultra-fast-acting insulin analogues in patients with type 1 diabetes. These publications build upon what is currently known about the pharmacokinetic/pharmacodynamic profile of ultra-fast-acting insulin analogues by exploring their effects in special populations, such as elderly patients, and investigating how variations in dose may influence their ability to address postprandial hyperglycaemia.

    Learning objectives

    Following completion of this activity, participants should be able to:

    • Compare the pharmacokinetic/pharmacodynamic profile of fast-acting and ultra-fast-acting insulins when used in the insulin pump setting
    • Discuss the pharmacological properties of ultra-fast-acting insulins in elderly populations with type 1 diabetes
    • Describe the pharmacological properties of ultra-fast-acting insulins over a range of clinically relevant doses
    • Discuss the within-patient variability in the glucose-lowering effect of ultra-fast-acting insulins
    This course requires you to login. Don't have an account yet? Please register.
  • Selected article

    A comparison of pharmacokinetic and pharmacodynamic properties between faster-acting insulin aspart and insulin aspart in elderly subjects with type 1 diabetes mellitus

    In this activity, you will be introduced to three recently published articles selected for their further exploration of the pharmacological properties of ultra-fast-acting insulin analogues in patients with type 1 diabetes. These publications build upon what is currently known about the pharmacokinetic/pharmacodynamic profile of ultra-fast-acting insulin analogues by exploring their effects in special populations, such as elderly patients, and investigating how variations in dose may influence their ability to address postprandial hyperglycaemia.

    Learning objectives

    Following completion of this activity, participants should be able to:

    • Compare the pharmacokinetic/pharmacodynamic profile of fast-acting and ultra-fast-acting insulins when used in the insulin pump setting
    • Discuss the pharmacological properties of ultra-fast-acting insulins in elderly populations with type 1 diabetes
    • Describe the pharmacological properties of ultra-fast-acting insulins over a range of clinically relevant doses
    • Discuss the within-patient variability in the glucose-lowering effect of ultra-fast-acting insulins
    This course requires you to login. Don't have an account yet? Please register.
  • Final assessment

    Please answer the final assessment questions in order to complete this course.

    This course requires you to login. Don't have an account yet? Please register.
  • UEMS accreditation test

    Please remember the following points while taking this assessment:

    • The assessment consists of 10 questions
    • You need to score a minimum of 80% to pass the assessment
    • Read the question carefully, select an option provided below the question, and then click the “Submit” button
    • You cannot change the answer once you have clicked the “Submit” button
    • If you exit the assessment before completing all the questions, you will have to attempt it again from the beginning.

    Validity of accreditation: 2 years after date of accreditation by: UEMS-EACCME

    >> Click Start when you are ready to take the assessment

    This course requires you to login. Don't have an account yet? Please register.
  • e-Learning Material Evaluation

    Clinical Efficacy, Safety and Pharmacology of Ultra-Fast-Acting Insulins

    The aim of this evaluation process is to maintain high educational standards and provide a reference for continuous improvement.

    In order to receive your certificate please complete this survey.

    This course requires you to login. Don't have an account yet? Please register.